These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 36853812)
1. Cefditoren: a clinical overview. Giuliano S; Acquasanta A; Martini L; Sbrana F; Flammini S; Tascini C New Microbiol; 2023 Feb; 46(1):9-17. PubMed ID: 36853812 [TBL] [Abstract][Full Text] [Related]
2. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents. Peric M; Browne FA; Jacobs MR; Appelbaum PC Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118 [TBL] [Abstract][Full Text] [Related]
3. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Biedenbach DJ; Jones RN Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284 [TBL] [Abstract][Full Text] [Related]
4. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769 [TBL] [Abstract][Full Text] [Related]
5. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Jones RN; Pfaller MA; Jacobs MR; Appelbaum PC; Fuchs PC Diagn Microbiol Infect Dis; 2001; 41(1-2):1-14. PubMed ID: 11687308 [TBL] [Abstract][Full Text] [Related]
7. Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren. Tempera G; Furneri PM; Carlone NA; Cocuzza C; Rigoli R; Musumeci R; Pilloni AP; Prenna M; Tufano MA; Tullio V; Vitali LA; Nicoletti G J Chemother; 2010 Jun; 22(3):153-9. PubMed ID: 20566418 [TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Johnson DM; Biedenbach DJ; Beach ML; Pfaller MA; Jones RN Diagn Microbiol Infect Dis; 2000 Jun; 37(2):99-105. PubMed ID: 10863104 [TBL] [Abstract][Full Text] [Related]
9. Cefditoren, a new aminothiazolyl cephalosporin. Balbisi EA Pharmacotherapy; 2002 Oct; 22(10):1278-93. PubMed ID: 12389878 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China. Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692 [TBL] [Abstract][Full Text] [Related]
12. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy. Stefani S; Mezzatesta ML; Fadda G; Mattina R; Palù G; Rossano F; Tufano MA; Schito GC; Nicoletti G J Chemother; 2008 Oct; 20(5):561-9. PubMed ID: 19028617 [TBL] [Abstract][Full Text] [Related]
13. Cefditoren in upper and lower community-acquired respiratory tract infections. Soriano F; Giménez MJ; Aguilar L Drug Des Devel Ther; 2011 Feb; 5():85-94. PubMed ID: 21340042 [TBL] [Abstract][Full Text] [Related]
14. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Wellington K; Curran MP Drugs; 2004; 64(22):2597-618. PubMed ID: 15516158 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries. Lee MY; Ko KS; Oh WS; Park S; Lee JY; Baek JY; Suh JY; Peck KR; Lee NY; Song JH Int J Antimicrob Agents; 2006 Jul; 28(1):14-8. PubMed ID: 16777383 [TBL] [Abstract][Full Text] [Related]
18. In vitro study of the post-antibiotic effect and the bactericidal activity of Cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens. Dubois J; St-Pierre C Diagn Microbiol Infect Dis; 2000 Jul; 37(3):187-93. PubMed ID: 10904192 [TBL] [Abstract][Full Text] [Related]
19. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462 [TBL] [Abstract][Full Text] [Related]
20. [Cefditoren pivoxil: A new oral cephalosporin for skin, soft tissue and respiratory tract infections]. Hernández-Martin J; Romá E; Salavert M; Doménech L; Poveda JL Rev Esp Quimioter; 2006 Sep; 19(3):231-46. PubMed ID: 17099791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]